A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Study Name
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
ClinicalTrials.gov Identifier (if applicable)
NCT05199584
Clinical Trial Category (check all that apply)
  • Targeted Therapy
Study Center
Institution Name
Endeavor Biomedicines
State
Country
United States
List additional Institutions (include address, phone number, and website)
Sites are located all across the United States, with the ability to open additional locations closer to a patient’s home.
Study Contacts
Principal Investigator
Endeavor Clinical Trials
P.I. Phone
(858) 727-3199
P.I. Email
ebmclinical@endeavorbiomedicines.com
Study Coordinator
Endeavor Clinical Trials
Study Coordinator Phone
(858) 727-3199
Study Coordinator Email
ebmclinical@endeavorbiomedicines.com
OVERVIEW – in layman’s terms (150 words max)
The study drug, ENV-101, acts on a protein in the body that is thought to be involved with the
growth of these abnormal cells caused by a mutation of a gene, PTCH1. By blocking this
process, ENV-101 may slow the progress of the disease or you may have a partial or complete
response.
More Information
The Future of Cancer Treatments: How Next Generation Sequencing can Optimize Treatments – YouTube
Enrollment
Ongoing
Study Start Date
12/01/2021
Estimated Completion Date
12/31/2023